-
Mashup Score: 1Weight-Loss Drug Zepbound Faces Supply Issues - 15 day(s) ago
Following weight-loss indication, patients struggle to obtain tirzepatide
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Weight-Loss Drug Zepbound Faces Supply Issues - 16 day(s) ago
Following weight-loss indication, patients struggle to obtain tirzepatide
Source: www.medpagetoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 22Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes - 2 month(s) ago
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists on the risk of major adverse liver outcomes (MALO) in patients with any chronic liver disease and type 2 diabetes. Design We used observational data from Swedish healthcare registers 2010–2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. We used an inverse-probability weighted marginal structural model to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation or MALO-related death) in initiators of GLP1 agonists with non-initiators. We randomly sampled 5% of the non-initiators to increase computational efficiency. Results GLP1 agonist initiators had a 10-year risk of MALO at 13.3% (42/1026) vs 14.6% in non-init
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 15
Download scientific diagram | The metabolic actions of GLP-1 in different organs and cell types. The actions shown are those with translational relevance predominantly conserved across species. For comparison of the actions of GIP vs GLP-1, please see review by Hammoud and Drucker [174]. Adapted from Drucker [100] with permission from Elsevier. This figure is available as part of a downloadable slideset from publication: The expanding incretin universe: from basic biology to clinical translation | Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(GLP-1), potentiate meal-stimulated insulin secretion through direct (GIP + GLP-1) and indirect (GLP-1) actions on islet β-cells. GIP and GLP-1 also regulate glucagon… | Incretins, Glucagon-Like Peptide 1 and Obesity | ResearchGate, the professional network for scientists.
Source: www.researchgate.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Omada GLP-1 program to prioritize muscle mass restoration through expanded care track - 2 month(s) ago
Chronic care provider Omada Health is expanding its GLP-1 program to better care for patients interested in maintaining weight loss progress while discontinuing usage of the drugs. | Omada executives shared they are expanding upon its GLP-1 Care Track, pushed by the belief that helping patients regain muscle mass is a critical to weight maintenance after tapering off utilization.
Source: www.fiercehealthcare.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 22Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes - 2 month(s) ago
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists on the risk of major adverse liver outcomes (MALO) in patients with any chronic liver disease and type 2 diabetes. Design We used observational data from Swedish healthcare registers 2010–2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. We used an inverse-probability weighted marginal structural model to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation or MALO-related death) in initiators of GLP1 agonists with non-initiators. We randomly sampled 5% of the non-initiators to increase computational efficiency. Results GLP1 agonist initiators had a 10-year risk of MALO at 13.3% (42/1026) vs 14.6% in non-init
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 21Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes - 3 month(s) ago
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists on the risk of major adverse liver outcomes (MALO) in patients with any chronic liver disease and type 2 diabetes. Design We used observational data from Swedish healthcare registers 2010–2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. We used an inverse-probability weighted marginal structural model to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation or MALO-related death) in initiators of GLP1 agonists with non-initiators. We randomly sampled 5% of the non-initiators to increase computational efficiency. Results GLP1 agonist initiators had a 10-year risk of MALO at 13.3% (42/1026) vs 14.6% in non-init
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 22Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes - 3 month(s) ago
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists on the risk of major adverse liver outcomes (MALO) in patients with any chronic liver disease and type 2 diabetes. Design We used observational data from Swedish healthcare registers 2010–2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. We used an inverse-probability weighted marginal structural model to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation or MALO-related death) in initiators of GLP1 agonists with non-initiators. We randomly sampled 5% of the non-initiators to increase computational efficiency. Results GLP1 agonist initiators had a 10-year risk of MALO at 13.3% (42/1026) vs 14.6% in non-init
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 21Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes - 3 month(s) ago
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists on the risk of major adverse liver outcomes (MALO) in patients with any chronic liver disease and type 2 diabetes. Design We used observational data from Swedish healthcare registers 2010–2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. We used an inverse-probability weighted marginal structural model to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation or MALO-related death) in initiators of GLP1 agonists with non-initiators. We randomly sampled 5% of the non-initiators to increase computational efficiency. Results GLP1 agonist initiators had a 10-year risk of MALO at 13.3% (42/1026) vs 14.6% in non-init
Source: gut.bmj.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Noom, Liviniti partner on GLP-1 Companion platform - 3 month(s) ago
The offering will be available to plan sponsors and their employees within the Noom for Work employer program.
Source: www.mobihealthnews.comCategories: General Medicine News, General HCPsTweet
"She felt like she was buying toilet paper during COVID; she's going to take it home on the T and she feels like she has to extra protect it." -- Jody Dushay, MD, about one of her patients who recently picked up a refill for a scarce #GLP1 agonist drug. https://t.co/0wOiBzSHdF